518 studies found for:    Open Studies | "Multiple Myeloma"
Show Display Options
Rank Status Study
21 Recruiting Autologous Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
22 Recruiting Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Placebo
23 Recruiting Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone
24 Unknown  Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
Conditions: Multiple Myeloma;   Peripheral Neuropathy
Intervention: Procedure: EMG
25 Recruiting Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: KPT-8602
26 Recruiting Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Nelfinavir;   Drug: Lenalidomide;   Drug: Dexamethasone
27 Recruiting Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: ABBV-838
28 Unknown  Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride
29 Recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
30 Not yet recruiting Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
31 Not yet recruiting Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
32 Unknown  Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone
33 Recruiting Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Carfilzomib;   Drug: Dexamethasone
34 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Dexamethasone
35 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
36 Not yet recruiting A Safety Study to Determine Dose and Tolerability of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: CC-220;   Drug: Dexamethasone
37 Unknown  High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
38 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: ABT-199;   Drug: Dexamethasone
39 Unknown  Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
Condition: Multiple Myeloma
Intervention: Procedure: Hematopoietic Stem Cell Transplantation
40 Unknown  Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years